Navigation Links
Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
Date:1/23/2013

LONDON, Jan. 23, 2013 /PRNewswire/ -- In a shaky economic climate, where fund raising has become tight and there are decreasing opportunities to exit the market, venture capital (VC) firms have become extremely cautious in choosing their investments. This has led to the trend of low value deals. However, segments like healthcare equipment have got sizeable injections of new funding, with such positive trends set to continue.

New analysis from Frost & Sullivan (http://www.financialservices.frost.com), Analysis of Venture Capital Investment Trends in the European Healthcare Industry, notes that drug delivering technologies and those focusing on product life cycle management of existing drugs are expected to attract VC investments.

"Patent expiration and lengthy approval times have increased the costs of drug development," says Frost & Sullivan Financial Analyst Dr. E. Saneesh. "This, coupled with a slowing economy, has made VC investors reluctant to invest more in new drug development. Instead, they have focused on enhanced drug delivery technologies and product life cycle management technologies."

While investments in pharmaceuticals and biotechnology decreased from 2010 to March 2012, healthcare equipment displayed sustained investments.

"Healthcare equipment is attracting VC investments because the innovations in this segment reduce the healthcare delivery costs, making the delivery easier," explains Dr. Saneesh. "Shorter product development cycles result in faster returns and, moreover, product approvals here are not as complex as those required for drugs."

However, regulatory variations across countries present a barrier for companies wanting to access VC funding. This has also affected fund raising efforts by VC firms.

Another concern is that the high costs and extended approval times related to drug development have decreased the chances of an early exit for VCs expecting a faster return on their investments.

"With the doors of IPO almost shut for them, VCs are now looking at new routes for exit," states Dr. Saneesh. "With the increase of strategic investments and corporate venturing in pharmaceuticals and biotechnology segments, mergers and acquisitions and strategic buyouts have become attractive exit options."

Technologies which reduce healthcare costs and enable safer and faster healthcare delivery are set to attract VC investments. New taxation laws and proposals to establish uniform EU-wide regulations for VC funds will further boost confidence levels.

If you are interested in more information on this study, please send an email with your contact details to Anna Zanchi , Corporate Communications, at anna.zanchi@frost.com

Analysis of Venture Capital Investment Trends in the European Healthcare Industry is part of the Financial Benchmarking in the Business and Financial Services Industry subscription, which also includes research services in the following markets: Venture Capital Investment Trends in Financial Services industry, Aerospace and Defense Industry, Automotive Industry. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

Frost & Sullivan's Business and Financial Services group serves clients around the world in all aspects of financial analysis, market research and monitoring, due diligence, idea generation, opportunity analysis, investment valuation, and other proprietary research.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion
Join Us:           Join our community
Subscribe:       Newsletter on "the next big thing"
Register:         Gain access to visionary innovation

Contact
Anna Zanchi
Corporate Communications – Europe
P: 0039 02 4851 6133
E: anna.zanchi@frost.com
http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
2. Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock
3. Omeros Announces Proposed Public Offering of Common Stock
4. Ampio Pharmaceuticals Announces Proposed Public Offering
5. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
6. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
7. Johnson & Johnson Provides Notice Of Proposed Settlement Of Shareholder Derivative Actions, Final Settlement Hearing, And Right To Appear
8. Verify Brand Supports the Proposed FDA Unique Device Identification (UDI) System for Medical Devices
9. Jason Pharmaceuticals, Inc. Reaches Proposed Consent Agreement with FTC
10. Solta Medical, Inc. Announces Proposed Public Offering of Common Stock
11. Isis Pharmaceuticals Announces Proposed Offering of $175 Million of Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... AVIV, Israel, March 23, 2017  Galmed Pharmaceuticals ... the "Company"), a clinical-stage biopharmaceutical company focused on ... the treatment of nonalcoholic steatohepatitis, or NASH, and ... the three and twelve months ended December 31, 2016, ... completed pre-clinical studies demonstrating Aramchol™,s potential direct effect ...
(Date:3/23/2017)... PUNE, India , March 23, 2017 ... 2022 report focuses on the Colposcope in Global market, especially in ... and Asia-Pacific , South America ... . This report categorizes the market based on manufacturers, regions, ... ...
(Date:3/23/2017)... SAN FRANCISCO , March 23, 2017 ... reach a value of USD 25.7 billion by 2025, according ... devices are expected to grow at a faster rate due ... to rising awareness about various types of esthetic procedures used ... from these disorders. Hence, they are considered as the highest ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... ... Inflow IQ & Inflownomics of Raleigh, NC introduce a powerful information access ... As experts in dangerous situations the Inflow IQ team can help people. Get ... clean & refreshing knowledge systems that enhance life. , Authentically enjoy ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Leaders ... life-altering and fatal diseases in opposition to the President’s Fiscal Year 2018 ... care, services, and hope for the most vulnerable among us. , The proposed ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... with European Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An ... http://www.fdanews.com/mdclineval                  , How will the new EU MDR language change ...
(Date:3/23/2017)... DC (PRWEB) , ... March 23, 2017 , ... News ... Dental Choice has helped score a major victory in Europe for public health and ... , Based on rigorous scientific research and the overwhelming support of European ...
(Date:3/23/2017)... ... March 23, 2017 , ... “My Journey Through Heaven”: the ... an infinitely more profound faith of God’s promise of Heaven for His people. “My ... spends each day with his wife, three children and six grandchildren living and doing ...
Breaking Medicine News(10 mins):